FARINA, NICOLA
 Distribuzione geografica
Continente #
EU - Europa 213
NA - Nord America 195
AS - Asia 52
Totale 460
Nazione #
US - Stati Uniti d'America 195
SE - Svezia 110
IT - Italia 71
CN - Cina 34
FI - Finlandia 12
IE - Irlanda 6
SG - Singapore 6
DE - Germania 5
PH - Filippine 4
GB - Regno Unito 3
IN - India 3
BE - Belgio 2
FR - Francia 2
IR - Iran 2
JP - Giappone 2
IL - Israele 1
NL - Olanda 1
UA - Ucraina 1
Totale 460
Città #
Shanghai 28
Ashburn 23
Lawrence 20
Princeton 20
Boardman 17
New York 16
Milan 14
Rome 13
Helsinki 12
Los Angeles 4
Quezon City 4
Seattle 4
Ancona 3
Ballincollig 3
Dublin 3
Osimo 3
Poli 3
Pune 3
San Giuliano 3
Vittoria 3
York 3
Bosco Chiesanuova 2
Castel Mella 2
Dalmine 2
Florence 2
Ghent 2
Honcho 2
Singapore 2
Verona 2
Amsterdam 1
Bologna 1
Giv‘atayim 1
Hangzhou 1
Isfahan 1
Modena 1
Paris 1
San Mateo 1
Santa Clara 1
Trentola-Ducenta 1
Trumbull 1
Turin 1
Washington 1
Totale 231
Nome #
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 33
Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia 29
POS0726 POST-TRAUMATIC STRESS DISORDER AND QUALITY OF LIFE IN SYSTEMIC LUPUS ERYTHEMATOSUS. A CROSS SECTIONAL WEB SURVEY-BASED STUDY 28
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 27
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 26
Biobanking for COVID-19 research 26
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 22
Obesity and its role in the management of rheumatoid and psoriatic arthritis 22
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 20
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 19
Post-traumatic stress disorder in patients with systemic lupus erythematosus heavily affects quality of life. A cross-sectional web survey-based study 18
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 18
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function 17
COVID-19: Pharmacology and kinetics of viral clearance 17
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 17
Drug retention rates of biological agents in adult onset Still's disease 17
Current treatment options and safety considerations when treating adult-onset Still’s disease 16
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 15
Loss of circulating CD8+ CD161high T cells in primary progressive multiple sclerosis 15
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 15
Low prevalence of arrhythmias in clinically stable COVID-19 patients 12
Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis 12
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 11
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 11
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 10
Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year 9
Interleukin 6 inhibition in severe COVID-19: Another piece of the puzzle 8
Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort 7
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 6
Catastrophic antiphospholipid syndrome presenting with aortic barrage: case report and review of the literature 5
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 4
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 4
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 4
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 3
Totale 523
Categoria #
all - tutte 5.895
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.895


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010 0 0 0 0 0 0 0 0 0 2 7 1
2020/202119 1 0 3 1 0 6 4 1 0 0 2 1
2021/202248 1 0 12 14 2 0 1 1 6 7 0 4
2022/2023216 50 43 16 6 12 25 20 25 4 2 6 7
2023/2024230 11 26 32 27 26 28 14 27 0 4 13 22
Totale 523